A probiotic strain of the bacteria Bacillus subtilis called PXN21 can prevent the buildup of the protein alpha-synuclein — one of the hallmarks of Parkinson’s disease — in the round worm C. elegans, researchers reports. This finding warrants further investigation to assess the therapeutic potential of dietary…

Roche presented initial data from an ongoing Phase 2 clinical trial evaluating prasinezumab (PRX002/RG7935) — an antibody against the alpha-synuclein protein — in more than 300 people with early stage Parkinson’s disease. Data highlighted that the trial’s participants, including those on MAO-B inhibitors, represent a wider population…

Delivering a gene therapy directly to the substantia nigra, an area of the brain affected by Parkinson’s disease, led to sustained protein production for up to eight years, a post-mortem of analysis of two patients revealed. The therapy’s use failed to show…

Scientists have discovered a “master controller” region that regulates aggregation of the alpha-synuclein protein, one of the distinctive features of Parkinson’s disease that is known to lead to the progressive degeneration of brain cells. Understanding how the master controller works opens new opportunities in both the…

Annovis Bio’s lead investigative therapy ANVS401 (also known as Posiphen) targeting protein buildup in the brain has been granted a U.S. patent as a way of treating Parkinson’s disease, Lewy body dementia, and other Lewy body disorders. The company, previously known as QR Pharma,…

RTB101, an investigational therapy being developed to treat Parkinson’s disease, is well-tolerated, can cross the blood-brain barrier, and reaches potentially therapeutic concentrations in cerebrospinal fluid (CSF), according to interim results of a Phase 1b/2a study. Developed by resTORbio, RTB101 is an orally-administered compound meant…

Increasing evidence links insulin-like growth factor 1 (IGF-1) deficiency to the development and progression of Parkinson’s disease, a review study said. Estrogen, the female sex hormone thought to hold potential beneficial effects against Parkinson’s, or PD, may exert its protective actions via IGF-1, the researchers said.

Memory-related mild cognitive impairment in Parkinson’s disease may be associated with a more severe buildup of alpha-synuclein protein in the brain — such as that observed in more advanced stages of the disease, a study finds. The results of the study, “Neuropathological Findings in Parkinson’s Disease With…

Seelos Therapeutics will begin animal studies to test a gene therapy approach to deliver its investigational candidate SLS-007 for Parkinson’s disease. SLS-007, originally developed by scientists at the University of California, Los Angeles, is intended to lessen the aggregation, or clumping, of alpha-synuclein protein —…

The U.S. Food and Drug Administration (FDA) has responded to Affiris‘  pre-investigational new drug (IND) submission regarding a planned Phase 2 clinical trial of the potential Parkinson’s vaccine Affitope (PD01A). After reviewing previous preclinical and clinical data, the FDA answered questions posed by the company…